bb102
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 29, 2022 (NCT06258408)
Timeline
Indications
Mechanism of action
- Fibroblast growth factor receptor 4INHIBITOR
FGFR4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07239986 | Phase 2 | Dec 31, 2025 | Broadenbio Ltd., Co. |
| NCT06258408 | Phase 1 | Dec 29, 2022 | Broncus Medical, Henan Medical University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Broadenbio Ltd., Co. | For profit | 1 | 1 | 1 | 2025 |
| Broncus Medical | For profit | 1 | 1 | 1 | 2022 |
| Henan Medical University | Academic/Hospital | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1